Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Cosentyx® (secukinumab) – Expanded indication
May 28, 2021 - The FDA approved Novartis’ Cosentyx (secukinumab), for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.
